DIH Holding US, Inc. (DHAI) Stock Competitors & Peer Comparison

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DHAI is priced at $0.00, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DHAI's ROE is +0.22%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, DHAI is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSX-PA's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ABT has a market cap of 157.5B. Regarding current trading prices, DHAI is priced at $0.00, while ABT trades at $91.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 25.33. In terms of profitability, DHAI's ROE is +0.22%, compared to ABT's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ABT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ISRG has a market cap of 148.2B. Regarding current trading prices, DHAI is priced at $0.00, while ISRG trades at $428.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ISRG's P/E ratio is 50.86. In terms of profitability, DHAI's ROE is +0.22%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, DHAI is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ISRG's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SYK has a market cap of 115.6B. Regarding current trading prices, DHAI is priced at $0.00, while SYK trades at $309.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 34.86. In terms of profitability, DHAI's ROE is +0.22%, compared to SYK's ROE of +0.15%. Regarding short-term risk, DHAI is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SYK's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, MDT has a market cap of 103.6B. Regarding current trading prices, DHAI is priced at $0.00, while MDT trades at $82.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 21.63. In terms of profitability, DHAI's ROE is +0.22%, compared to MDT's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MDT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BSX has a market cap of 72.4B. Regarding current trading prices, DHAI is priced at $0.00, while BSX trades at $49.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 20.38. In terms of profitability, DHAI's ROE is +0.22%, compared to BSX's ROE of +0.15%. Regarding short-term risk, DHAI is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BRKRP has a market cap of 63.7B. Regarding current trading prices, DHAI is priced at $0.00, while BRKRP trades at $426.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is N/A. In terms of profitability, DHAI's ROE is +0.22%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, DHAI is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BRKRP's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, DHAI is priced at $0.00, while EW trades at $86.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas EW's P/E ratio is 46.41. In terms of profitability, DHAI's ROE is +0.22%, compared to EW's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EW's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, DXCM has a market cap of 29.6B. Regarding current trading prices, DHAI is priced at $0.00, while DXCM trades at $78.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 32.88. In terms of profitability, DHAI's ROE is +0.22%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, DHAI is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check DXCM's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, RMD has a market cap of 28B. Regarding current trading prices, DHAI is priced at $0.00, while RMD trades at $196.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas RMD's P/E ratio is 18.63. In terms of profitability, DHAI's ROE is +0.22%, compared to RMD's ROE of +0.24%. Regarding short-term risk, DHAI is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check RMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PHG has a market cap of 25.1B. Regarding current trading prices, DHAI is priced at $0.00, while PHG trades at $26.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 22.25. In terms of profitability, DHAI's ROE is +0.22%, compared to PHG's ROE of +0.09%. Regarding short-term risk, DHAI is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PHG's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, STE has a market cap of 20.5B. Regarding current trading prices, DHAI is priced at $0.00, while STE trades at $212.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas STE's P/E ratio is 26.53. In terms of profitability, DHAI's ROE is +0.22%, compared to STE's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check STE's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DHAI is priced at $0.00, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DHAI's ROE is +0.22%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ABMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ZBH has a market cap of 16.9B. Regarding current trading prices, DHAI is priced at $0.00, while ZBH trades at $88.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 22.62. In terms of profitability, DHAI's ROE is +0.22%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, DHAI is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ZBH's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, DHAI is priced at $0.00, while SNN trades at $31.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 21.22. In terms of profitability, DHAI's ROE is +0.22%, compared to SNN's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SNN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, DHAI is priced at $0.00, while PEN trades at $321.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 73.91. In terms of profitability, DHAI's ROE is +0.22%, compared to PEN's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PEN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DHAI is priced at $0.00, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DHAI's ROE is +0.22%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, DHAI is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SWAV's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ALGN has a market cap of 12.3B. Regarding current trading prices, DHAI is priced at $0.00, while ALGN trades at $177.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 28.92. In terms of profitability, DHAI's ROE is +0.22%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ALGN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, DHAI is priced at $0.00, while GMED trades at $81.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 18.30. In terms of profitability, DHAI's ROE is +0.22%, compared to GMED's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check GMED's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, DHAI is priced at $0.00, while PODD trades at $158.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 35.40. In terms of profitability, DHAI's ROE is +0.22%, compared to PODD's ROE of +0.21%. Regarding short-term risk, DHAI is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PODD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, DHAI is priced at $0.00, while MASI trades at $179.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas MASI's P/E ratio is 44.54. In terms of profitability, DHAI's ROE is +0.22%, compared to MASI's ROE of +0.09%. Regarding short-term risk, DHAI is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MASI's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, DHAI is priced at $0.00, while BRKR trades at $57.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is -234.42. In terms of profitability, DHAI's ROE is +0.22%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, DHAI is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BRKR's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BIO-B has a market cap of 8.3B. Regarding current trading prices, DHAI is priced at $0.00, while BIO-B trades at $307.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is 51.10. In terms of profitability, DHAI's ROE is +0.22%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, DHAI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BIO-B's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BIO has a market cap of 7.9B. Regarding current trading prices, DHAI is priced at $0.00, while BIO trades at $295.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 48.58. In terms of profitability, DHAI's ROE is +0.22%, compared to BIO's ROE of +0.02%. Regarding short-term risk, DHAI is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BIO's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, GKOS has a market cap of 7.2B. Regarding current trading prices, DHAI is priced at $0.00, while GKOS trades at $127.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -37.00. In terms of profitability, DHAI's ROE is +0.22%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, DHAI is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check GKOS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DHAI is priced at $0.00, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, DHAI's ROE is +0.22%, compared to NARI's ROE of -0.00%. Regarding short-term risk, DHAI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NARI's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, DHAI is priced at $0.00, while LIVN trades at $77.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is 38.16. In terms of profitability, DHAI's ROE is +0.22%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, DHAI is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LIVN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DHAI is priced at $0.00, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DHAI's ROE is +0.22%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DHAI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AXNX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, DHAI is priced at $0.00, while IRTC trades at $110.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -126.15. In terms of profitability, DHAI's ROE is +0.22%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, DHAI is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IRTC's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, DHAI is priced at $0.00, while ITGR trades at $93.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 22.79. In terms of profitability, DHAI's ROE is +0.22%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, DHAI is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ITGR's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, DHAI is priced at $0.00, while TMDX trades at $73.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 16.28. In terms of profitability, DHAI's ROE is +0.22%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, DHAI is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TMDX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, DHAI is priced at $0.00, while AXGN trades at $42.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is -64.78. In terms of profitability, DHAI's ROE is +0.22%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, DHAI is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AXGN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, DHAI is priced at $0.00, while ESTA trades at $77.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -50.91. In terms of profitability, DHAI's ROE is +0.22%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, DHAI is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ESTA's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DHAI is priced at $0.00, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DHAI's ROE is +0.22%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DHAI is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NUVA's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, DHAI is priced at $0.00, while UFPT trades at $230.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 25.82. In terms of profitability, DHAI's ROE is +0.22%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, DHAI is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check UFPT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PRCT has a market cap of 1.6B. Regarding current trading prices, DHAI is priced at $0.00, while PRCT trades at $28.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -15.49. In terms of profitability, DHAI's ROE is +0.22%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, DHAI is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PRCT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, DHAI is priced at $0.00, while ENOV trades at $24.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ENOV's P/E ratio is -1.19. In terms of profitability, DHAI's ROE is +0.22%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, DHAI is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ENOV's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, DHAI is priced at $0.00, while IART trades at $17.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas IART's P/E ratio is -2.62. In terms of profitability, DHAI's ROE is +0.22%, compared to IART's ROE of -0.48%. Regarding short-term risk, DHAI is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IART's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, DHAI is priced at $0.00, while AHCO trades at $9.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is -16.36. In terms of profitability, DHAI's ROE is +0.22%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, DHAI is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AHCO's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DHAI is priced at $0.00, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DHAI's ROE is +0.22%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DHAI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check HSKA's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, DHAI is priced at $0.00, while TNDM trades at $18.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -13.48. In terms of profitability, DHAI's ROE is +0.22%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, DHAI is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TNDM's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while BFLY trades at $5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -15.90. In terms of profitability, DHAI's ROE is +0.22%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, DHAI is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BFLY's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while ATEC trades at $8.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -9.53. In terms of profitability, DHAI's ROE is +0.22%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, DHAI is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ATEC's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while INSP trades at $42.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 9.53. In terms of profitability, DHAI's ROE is +0.22%, compared to INSP's ROE of +0.18%. Regarding short-term risk, DHAI is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INSP's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while IRMD trades at $95.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 51.58. In terms of profitability, DHAI's ROE is +0.22%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, DHAI is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IRMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while AVNS trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is -15.63. In terms of profitability, DHAI's ROE is +0.22%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, DHAI is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AVNS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DHAI is priced at $0.00, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, DHAI's ROE is +0.22%, compared to SILK's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SILK's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DHAI is priced at $0.00, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, DHAI's ROE is +0.22%, compared to FNA's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check FNA's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CNMD has a market cap of 1B. Regarding current trading prices, DHAI is priced at $0.00, while CNMD trades at $36.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 19.48. In terms of profitability, DHAI's ROE is +0.22%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, DHAI is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CNMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AORT has a market cap of 989.3M. Regarding current trading prices, DHAI is priced at $0.00, while AORT trades at $20.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 81.52. In terms of profitability, DHAI's ROE is +0.22%, compared to AORT's ROE of +0.03%. Regarding short-term risk, DHAI is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AORT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DHAI is priced at $0.00, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, DHAI's ROE is +0.22%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DHAI is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CSII's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, INMD has a market cap of 820.9M. Regarding current trading prices, DHAI is priced at $0.00, while INMD trades at $13.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 10.00. In terms of profitability, DHAI's ROE is +0.22%, compared to INMD's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, LMRI has a market cap of 781.1M. Regarding current trading prices, DHAI is priced at $0.00, while LMRI trades at $8.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -20.85. In terms of profitability, DHAI's ROE is +0.22%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, DHAI is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LMRI's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, DHAI is priced at $0.00, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CRY's P/E ratio is 425.71. In terms of profitability, DHAI's ROE is +0.22%, compared to CRY's ROE of +0.03%. Regarding short-term risk, DHAI is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CRY's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SSII has a market cap of 706.5M. Regarding current trading prices, DHAI is priced at $0.00, while SSII trades at $3.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -70.60. In terms of profitability, DHAI's ROE is +0.22%, compared to SSII's ROE of -0.23%. Regarding short-term risk, DHAI is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SSII's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CBLL has a market cap of 688.3M. Regarding current trading prices, DHAI is priced at $0.00, while CBLL trades at $18.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -11.20. In terms of profitability, DHAI's ROE is +0.22%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, DHAI is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CBLL's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SIBN has a market cap of 663.9M. Regarding current trading prices, DHAI is priced at $0.00, while SIBN trades at $15.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -38.38. In terms of profitability, DHAI's ROE is +0.22%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, DHAI is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SIBN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, DHAI is priced at $0.00, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, DHAI's ROE is +0.22%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, DHAI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SRDX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BVS has a market cap of 606.3M. Regarding current trading prices, DHAI is priced at $0.00, while BVS trades at $9.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 21.83. In terms of profitability, DHAI's ROE is +0.22%, compared to BVS's ROE of +0.16%. Regarding short-term risk, DHAI is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BVS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DHAI is priced at $0.00, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, DHAI's ROE is +0.22%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DHAI is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check APEN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, TCMD has a market cap of 569.5M. Regarding current trading prices, DHAI is priced at $0.00, while TCMD trades at $26.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 29.02. In terms of profitability, DHAI's ROE is +0.22%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TCMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BWAY has a market cap of 565.2M. Regarding current trading prices, DHAI is priced at $0.00, while BWAY trades at $14.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BWAY's P/E ratio is 65.50. In terms of profitability, DHAI's ROE is +0.22%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BWAY's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, DHAI is priced at $0.00, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, DHAI's ROE is +0.22%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, DHAI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ZIMV's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, NPCE has a market cap of 532.9M. Regarding current trading prices, DHAI is priced at $0.00, while NPCE trades at $16.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -24.05. In terms of profitability, DHAI's ROE is +0.22%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, DHAI is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NPCE's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CTKB has a market cap of 521.7M. Regarding current trading prices, DHAI is priced at $0.00, while CTKB trades at $4.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -6.97. In terms of profitability, DHAI's ROE is +0.22%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, DHAI is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CTKB's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CERS has a market cap of 521M. Regarding current trading prices, DHAI is priced at $0.00, while CERS trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -52.00. In terms of profitability, DHAI's ROE is +0.22%, compared to CERS's ROE of -0.15%. Regarding short-term risk, DHAI is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CERS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, KIDS has a market cap of 468.2M. Regarding current trading prices, DHAI is priced at $0.00, while KIDS trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -10.85. In terms of profitability, DHAI's ROE is +0.22%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, DHAI is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check KIDS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, VREX has a market cap of 433.2M. Regarding current trading prices, DHAI is priced at $0.00, while VREX trades at $10.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas VREX's P/E ratio is -5.14. In terms of profitability, DHAI's ROE is +0.22%, compared to VREX's ROE of -0.18%. Regarding short-term risk, DHAI is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check VREX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PACB has a market cap of 428.6M. Regarding current trading prices, DHAI is priced at $0.00, while PACB trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -3.37. In terms of profitability, DHAI's ROE is +0.22%, compared to PACB's ROE of -4.88%. Regarding short-term risk, DHAI is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PACB's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PMI has a market cap of 411.5M. Regarding current trading prices, DHAI is priced at $0.00, while PMI trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PMI's P/E ratio is -0.35. In terms of profitability, DHAI's ROE is +0.22%, compared to PMI's ROE of +4.99%. Regarding short-term risk, DHAI is more volatile compared to PMI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PMI's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CLPT has a market cap of 401.3M. Regarding current trading prices, DHAI is priced at $0.00, while CLPT trades at $13.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -13.38. In terms of profitability, DHAI's ROE is +0.22%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, DHAI is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CLPT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, OFIX has a market cap of 391.7M. Regarding current trading prices, DHAI is priced at $0.00, while OFIX trades at $9.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -6.46. In terms of profitability, DHAI's ROE is +0.22%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, DHAI is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check OFIX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, VMD has a market cap of 380.3M. Regarding current trading prices, DHAI is priced at $0.00, while VMD trades at $10.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 26.81. In terms of profitability, DHAI's ROE is +0.22%, compared to VMD's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check VMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, DCTH has a market cap of 377.7M. Regarding current trading prices, DHAI is priced at $0.00, while DCTH trades at $11.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 1094.00. In terms of profitability, DHAI's ROE is +0.22%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, DHAI is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check DCTH's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, AVR has a market cap of 343.6M. Regarding current trading prices, DHAI is priced at $0.00, while AVR trades at $9.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -4.21. In terms of profitability, DHAI's ROE is +0.22%, compared to AVR's ROE of -1.24%. Regarding short-term risk, DHAI is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AVR's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, LAB has a market cap of 313.5M. Regarding current trading prices, DHAI is priced at $0.00, while LAB trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas LAB's P/E ratio is -6.18. In terms of profitability, DHAI's ROE is +0.22%, compared to LAB's ROE of -0.21%. Regarding short-term risk, DHAI is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LAB's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, DHAI is priced at $0.00, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, DHAI's ROE is +0.22%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, DHAI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SMLR's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ELMD has a market cap of 307.1M. Regarding current trading prices, DHAI is priced at $0.00, while ELMD trades at $36.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 31.70. In terms of profitability, DHAI's ROE is +0.22%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, DHAI is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ELMD's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, MASS has a market cap of 306.3M. Regarding current trading prices, DHAI is priced at $0.00, while MASS trades at $8.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas MASS's P/E ratio is -8.35. In terms of profitability, DHAI's ROE is +0.22%, compared to MASS's ROE of -0.26%. Regarding short-term risk, DHAI is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MASS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SENS has a market cap of 297.8M. Regarding current trading prices, DHAI is priced at $0.00, while SENS trades at $7.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -3.62. In terms of profitability, DHAI's ROE is +0.22%, compared to SENS's ROE of -1.30%. Regarding short-term risk, DHAI is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SENS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, SGHT has a market cap of 251.9M. Regarding current trading prices, DHAI is priced at $0.00, while SGHT trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -6.61. In terms of profitability, DHAI's ROE is +0.22%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, DHAI is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SGHT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, DHAI is priced at $0.00, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -11.11. In terms of profitability, DHAI's ROE is +0.22%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, DHAI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MGRM's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, TMCI has a market cap of 229M. Regarding current trading prices, DHAI is priced at $0.00, while TMCI trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas TMCI's P/E ratio is -3.68. In terms of profitability, DHAI's ROE is +0.22%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, DHAI is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TMCI's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CATX has a market cap of 226M. Regarding current trading prices, DHAI is priced at $0.00, while CATX trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -2.07. In terms of profitability, DHAI's ROE is +0.22%, compared to CATX's ROE of -0.42%. Regarding short-term risk, DHAI is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CATX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DHAI is priced at $0.00, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DHAI's ROE is +0.22%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DHAI is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NVRO's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, EYES has a market cap of 210M. Regarding current trading prices, DHAI is priced at $0.00, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas EYES's P/E ratio is N/A. In terms of profitability, DHAI's ROE is +0.22%, compared to EYES's ROE of -2.64%. Regarding short-term risk, DHAI is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EYES's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, RXST has a market cap of 204.9M. Regarding current trading prices, DHAI is priced at $0.00, while RXST trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -4.38. In terms of profitability, DHAI's ROE is +0.22%, compared to RXST's ROE of -0.17%. Regarding short-term risk, DHAI is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check RXST's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, APYX has a market cap of 199.7M. Regarding current trading prices, DHAI is priced at $0.00, while APYX trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas APYX's P/E ratio is -21.68. In terms of profitability, DHAI's ROE is +0.22%, compared to APYX's ROE of -0.91%. Regarding short-term risk, DHAI is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check APYX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, PROF has a market cap of 198.8M. Regarding current trading prices, DHAI is priced at $0.00, while PROF trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.30. In terms of profitability, DHAI's ROE is +0.22%, compared to PROF's ROE of -0.71%. Regarding short-term risk, DHAI is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PROF's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, ANIK has a market cap of 194.3M. Regarding current trading prices, DHAI is priced at $0.00, while ANIK trades at $14.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas ANIK's P/E ratio is -18.48. In terms of profitability, DHAI's ROE is +0.22%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, DHAI is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ANIK's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, DHAI is priced at $0.00, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, DHAI's ROE is +0.22%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, DHAI is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSGM's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, DHAI is priced at $0.00, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, DHAI's ROE is +0.22%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, DHAI is more volatile compared to MDGS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MDGS's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, DHAI is priced at $0.00, while EDAP trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas EDAP's P/E ratio is -5.80. In terms of profitability, DHAI's ROE is +0.22%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, DHAI is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EDAP's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, FOCL has a market cap of 172.4M. Regarding current trading prices, DHAI is priced at $0.00, while FOCL trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas FOCL's P/E ratio is -5.61. In terms of profitability, DHAI's ROE is +0.22%, compared to FOCL's ROE of -1.37%. Regarding short-term risk, DHAI is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check FOCL's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, INGN has a market cap of 164.1M. Regarding current trading prices, DHAI is priced at $0.00, while INGN trades at $6.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -6.66. In terms of profitability, DHAI's ROE is +0.22%, compared to INGN's ROE of -0.13%. Regarding short-term risk, DHAI is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INGN's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, DHAI is priced at $0.00, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.87. In terms of profitability, DHAI's ROE is +0.22%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, DHAI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check QIPT's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, QTRX has a market cap of 147.4M. Regarding current trading prices, DHAI is priced at $0.00, while QTRX trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas QTRX's P/E ratio is -1.33. In terms of profitability, DHAI's ROE is +0.22%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check QTRX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, CVRX has a market cap of 143.3M. Regarding current trading prices, DHAI is priced at $0.00, while CVRX trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas CVRX's P/E ratio is -2.69. In terms of profitability, DHAI's ROE is +0.22%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, DHAI is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CVRX's competition here

DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DHAI stands at 837. In comparison, NNOX has a market cap of 126.7M. Regarding current trading prices, DHAI is priced at $0.00, while NNOX trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DHAI currently has a P/E ratio of N/A, whereas NNOX's P/E ratio is -1.57. In terms of profitability, DHAI's ROE is +0.22%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, DHAI is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NNOX's competition here